

Home > DB Guides

Glossary of Risk Assessment Related Terms (N - Z)

Neoplasm: An abnormal growth of tissue which may be benign or malignant.

No-Observed-Adverse-Effect Level (NOAEL): An highest exposure level at which are no statistically or biologically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control; some may be produced at this level, but they are not considered adverse, nor precursors of adverse effects.

No-Observed-Effect Level (NOEL): An exposure level at which there are no statistically or biologically significant increases in the frequency or severity of any effect between exposed population and its appropriate control.

Non-linear dose response: A pattern of frequency or severity of biological response does not vary proportionately with the amount of dose of an agent. When more information indicates that responses may not follow a linear pattern below the dose of the observed data, non-linear methods for determining risk at low dose may be used.

Odds Ratio (OR): A relative measure of the difference in exposure between the diseased (cases) and not diseased (controls) individuals in a case-control study. The OR is interpreted similarly to the relative risk.

Oncogenic: Resulting from a gene which can induce neoplastic transformations in a cell in which it occurs or into which it is introduced.

One hit Model: A dose-response model based on a mechanistic argument that the response after a target site has been hit by a single biologically effective unit of dose within a given time period. The form of the model, a special case of the gamma, multistage, and Weibull models, is given by:

$$P(d) = 1 - \exp(-Id)$$

where $P(d)$ = probability of cancer from lifetime continuous exposure at dose rate d
 I = fitted dose coefficient.

Organoleptic: Affecting or involving a sense organ such as that of taste, smell, or touch.

Physiologically Based Pharmacokinetic (PBPK) Model: Physiologically based compartmental model used to characterize pharmacokinetic behavior of a chemical. Available data on blood flow rates, and metabolic and other processes which the chemical undergoes within each compartment are used to construct a mass-balance framework for the PBPK model.

Point of Departure: The dose-response point that marks the beginning of a low-dose response.

extrapolation. This point is most often the upper bound on an observed incidence, estimated incidence from a dose-response model.

ppb: A unit of measure expressed as parts per billion. Equivalent to 1×10^{-9} .

ppm: A unit of measure expressed as parts per million. Equivalent to 1×10^{-6} .

Prevalence: The proportion of disease cases that exist within a population at a specific point in time, relative to the number of individuals within that population at the same point in time.

Probit Model: A dose-response model of the form:

$$P(d) = g + ((1 - g) \times 1) / (\text{square root of } 2 \times \pi) \times \{ \text{integral from minus infinity to } a + bd \text{ of } [\exp(-(y^2)/2)] dy \}$$

where $P(d)$ = the probability that an individual selected at random will respond at a given dose, assuming a normal distribution of tolerances;

a, b = fitted parameters; and

g = background response rate.

Promoter: An agent that is not carcinogenic itself, but when administered after an agent that initiates carcinogenesis, stimulates the clonal expansion of the initiated cell to produce a neoplasm.

Proportionate Mortality Ratio (PMR): The proportion of deaths due to the disease of interest in the exposed population divided by the proportion of deaths due to the disease of interest in the unexposed or reference population. It is frequently converted to a standardized mortality ratio by multiplying the ratio by 100.

Prospective Study: See cohort study.

Reference Concentration (RfC): An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.

Reference Dose (RfD): An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.

Regional Deposited Dose (RDD): The deposited dose of particles calculated for a specific respiratory tract region of interest (r) as related to an observed toxicity. For respiratory effects of particles, the deposited dose is adjusted for ventilatory volumes and the area of the respiratory region effected ($\text{mg}/\text{min-sq. cm}$). For extra respiratory effects of particles, the deposited dose in the total respiratory system is adjusted for ventilatory volumes and body weight ($\text{mg}/\text{min-kg}$).

Regional Deposited Dose Ratio (RDDR): The ratio of the regional deposited dose calculated for a given exposure in the animal species of interest to the regional dose of the same exposure in a human. This ratio is used to adjust the exposure level for interspecies dosimetric differences to derive a human equivalent concentration for particles.

Regional Gas Dose: The gas dose calculated for the region of interest as related observed effect for respiratory effects. The deposited dose is adjusted for ventilatory volumes and the surface area of the respiratory region effected (mg/min-sq.cm).

Regional Gas Dose Ratio (RGDR): The ratio of the regional gas dose calculated given exposure in the animal species of interest to the regional gas dose of the same exposure in humans. This ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a human equivalent concentration for gases with respiratory effects.

Relative Risk (or Risk Ratio (RR)): The relative measure of the difference in risk between the exposed and unexposed populations in a cohort study. The relative risk is defined as the rate of disease among the exposed divided by the rate of the disease among the unexposed. A relative risk of 2 means that the exposed group has twice the disease risk as the unexposed group.

Reserve Volume: The volume of air remaining in the lungs after a maximal expiration.

Residual Volume (RV): The lung volume after maximal expiration (TLC - VC).

Risk (in the context of human health): The probability of injury, disease, or death from exposure to a chemical agent or a mixture of chemicals. In quantitative terms, risk is expressed in values ranging from zero (representing the certainty that harm will not occur) to one (representing the certainty that harm will occur). The following are example risks expressed within IRIS: $E-4$ or 10^{-4} = a risk of 1/10,000; $E-5$ or 10^{-5} = 1/100,000 or 10^{-6} = 1/1,000,000. Similarly, $1.3 E-3$ or 1.3×10^{-3} = a risk of 1.3/1,000 = 1/770 or 8×10^{-3} = a risk of 1/125 and $1.2 E-5$ or 1.2×10^{-5} = a risk of 1/83,000.

Risk Assessment (in the context of human health): The determination of potential adverse health effects from exposure to chemicals, including both quantitative and qualitative expressions of risk. The process of risk assessment involves four major steps: hazard identification, dose-response assessment, exposure assessment, and risk characterization.

Risk Management (in the context of human health): A decision making process that accounts for political, social, economic and engineering implications together with related information in order to develop, analyze and compare management options and select the appropriate managerial response to a potential chronic health hazard.

Short-Term Exposure: Multiple or continuous exposure to an agent for a short period of time, usually one week.

Sigma g: Geometric standard deviation. (See Mass Median Aerodynamic Diameter).

Slope Factor: An upper bound, approximating a 95% confidence limit, on the increase in cancer risk from a lifetime exposure to an agent. This estimate, usually expressed as a proportion (of a population) affected per mg/kg/day, is generally reserved for use in the low-dose region of the dose-response relationship, that is, for exposures corresponding to risks less than 1 in 100.

Standardized Mortality Ratio (SMR): This is the relative measure of the difference in risk between the exposed and unexposed populations in a cohort study. The SMR is similar to the relative risk in both definition and interpretation. This measure is usually standardized to control for any differences in age, sex, and/or race between the exposed and reference populations. It is frequently converted to a percent by multiplying the ratio by 100.

Statistical Significance: The probability that a result likely to be due to chance alone. By convention, a difference between two groups is usually considered statistically significant if chance could explain it only 5% of the time or less. Study design considerations influence the a priori choice of a different statistical significance level.

Subchronic Exposure: Exposure to a substance spanning approximately 10% of the lifetime of an organism.

Subchronic Study: A toxicity study designed to measure effects from subchronic exposure to a chemical.

Sufficient Evidence: A term used in evaluating study data for the classification of a chemical as a carcinogen under the 1986 U.S. EPA guidelines for carcinogen risk assessment. This classification indicates that there is a causal relationship between the agent or agent and human cancer.

Superfund: Federal authority, established by the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) in 1980, to respond directly to releases or threatened releases of hazardous substances that may endanger health and the environment.

Supporting Studies: Studies that contain information useful for providing insight and support for conclusions.

Systemic Effects or Systemic Toxicity: Toxic effects as a result of absorption and distribution of a toxicant to a site distant from its entry point, at which point effects are first produced. Not all chemicals that produce systemic effects cause the same degree of toxicity in all organs.

Target Organ: The biological organ(s) most adversely affected by exposure to a chemical substance.

Teratogenic: Structural developmental defects due to exposure to a chemical agent during formation of individual organs.

Threshold: The dose or exposure below which no deleterious effect is expected to occur.

Tidal Volume (VT): The volume of air inhaled/exhaled during normal breathing.

Total Lung Volume (TLV): The lung volume at maximal inspiration.

Toxicity: The degree to which a chemical substance elicits a deleterious or adverse effect upon the biological system of an organism exposed to the substance over a designated time period.

Toxicology: The study of harmful interactions between chemicals and biological systems.

Toxic Substance: A chemical substance or agent which may cause an adverse effect to biological systems.

Tumor: An abnormal, uncontrolled growth of cells. Synonym: neoplasm.

Tumor Progression: Under the Armitage-Doll multistage theory of cancer development, the transition of a cell line between the stages which lead to cancer.

Threshold Limit Value (TLV): Recommended guidelines for occupational exposure to airborne contaminants published by the American Conference of Governmental Industrial Hygienists (ACGIH). TLVs represent the average concentration in mg/m³ for an 8-hour workday and a 40-hour work week to which nearly all workers may be repeatedly exposed day after day, without adverse effect.

Uncertainty Factor (UF): One of several, generally 10-fold factors, used in operations for deriving the RfD and RfC from experimental data. UFs are intended to account for: (1) variation in sensitivity among the members of the human population, i.e., interhuman and intraspecies variability; (2) the uncertainty in extrapolating animal data to humans; (3) interspecies variability; (4) the uncertainty in extrapolating from data obtained in a subchronic exposure to lifetime exposure, i.e., extrapolating from subchronic to chronic exposure; (5) the uncertainty in extrapolating from a LOAEL rather than from a NOAEL; and (6) the uncertainty associated with extrapolation from animal data where the data base is incomplete.

Unit Risk: The upper-bound excess lifetime cancer risk estimated to result from continuous exposure to an agent at a concentration of 1 µg/L in water, or 1 µg/m³ in air. The interpretation of unit risk would be as follows: if unit risk = 1.5 x 10⁻⁶ µg/L, 1.5 tumors are expected to develop per 1,000,000 people if exposed daily for a lifetime to the chemical in 1 liter of drinking water.

Upper bound: An plausible upper limit to the true value of a quantity. This is usually the true statistical confidence limit.

Vital Capacity (VC): The maximum volume that can be exhaled in a single breath (after maximal inspiration).

Weibull Model: A dose-response model of the form:

$$P(d) = g + (1 - g)(1 - \exp -b[d ** a])$$


where P(d) = the probability of a tumor (or other response) from lifetime, continuous exposure at dose d until age t (when tumor is fatal);

a = fitted dose parameter (sometimes called "Weibull" parameter);

b = fitted dose parameter;

g = background response rate.

Weight-of-Evidence (WOE) for Carcinogenicity: A system used by the U.S. EPA for characterizing the extent to which the available data support the hypothesis that a chemical causes cancer in humans. Under EPA's 1986 risk assessment guidelines, the WOE is described by categories "A through E", Group A for known human carcinogens through Group E for agents with evidence of noncarcinogenicity. The approach outlined in the proposed guidelines for carcinogen risk assessment (1996) considers all scientific



information in determining whether and under what conditions an agent may cause cancer in humans, and provides a narrative approach to characterize carcinogenicity risk categories.